Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
Rift Valley FeverThis study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine
RVF and Other Emerging Infectious Diseases in East and Central Africa
Rift Valley FeverHemorrhagic Fevers1 moreRift Valley fever (RVF), a disease transmitted from livestock (cattle, sheep, goats, camels) to humans more commonly occurs in the East and Central Africa (ECA) regions where more than 15 major epidemics affecting more than one country have been reported over the past 50 years. Within the region, there are specific areas, referred to as hotspots, which support RVF virus maintenance via low-level virus circulation between animals, humans, and mosquitoes. Most outbreaks originate from these hotspots. Our goal is to conduct studies in RVF hotspots in four ECA countries, Kenya, Uganda, Tanzania, and Democratic Republic of Congo (DRC) to determine the burden of RVF disease among humans, wildlife and livestock during inter-epidemic periods (IEPs) and discover circulation of undetected infectious diseases. This information is important for use in developing an early warning system and possibly a vaccination strategy. The study will take place in Uganda, Kenya, Tanzania and Democratic Republic of Congo
Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)
Rift Valley FeverPhase I open label, non-randomised dose escalation study on healthy UK volunteers aged from 18 to 50 years to assess the safety and immunogenicity of ChAdOx1 RVF
Safety and Immunogenicity Study of Rift Valley Fever Vaccine
Rift Valley FeverThis study is designed to determine the safety and immunogenicity of a Rift Valley Fever (RVF) Vaccine
Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
Rift Valley FeverThis study is to determine if a vaccine for Rift Valley Fever (RVF) is safe to give to humans. The study will examine how well the vaccine (RVF MP-12) stimulates the body's immune response (which fights off infection) and if the vaccine is stable or if the virus used to make the vaccine changes into a different form once injected into the body. Twenty healthy volunteers (18-50 years old) will be vaccinated with a single dose of undiluted RVF MP-12, injected into a muscle.
A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults
RVFRift Valley FeverRandomised, single blind, placebo - controlled, dose-escalation, phase I clinical trial recruiting healthy adults aged 18-50 years
Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated
Rift Valley FeverThis study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults
Rift Valley Fever in Kenya
Rift Valley FeverThe purpose of this study is to find out how, why, and when Rift Valley Fever (RVF) spreads. Participants will be 250 adults and children, aged 1 year and older, from the Ijara District, Kenya. They will be given a questionnaire, undergo a medical examination that includes an eye exam, and have a 1-teaspoon sample of blood taken from a vein. Participation will take about 3 hours.